PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Date: 19.09.2026

To, Department of Corporate Services, **BSE LIMITED** P. J. Towers, Dalal Street, Mumbai, Maharashtra–400001. **ISIN : INE730E01016** **Scrip Code: 512217**	To, Listing Department, **Metropolitan Stock Exchange of India Limited (MSEI)** Vibgyor Towers, 4th Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra–400098. **SYMBOL: PRISMMEDI**

Subject: Outcome of 24th Annual General Meeting held on 19th September, 2026 at 12:30 P.M. through Video Conferencing/Other Audio-Visual Means.

Dear Sir/Madam,

The stock exchange(s) are hereby informed that the 24th Annual General Meeting of the members of the company was convened on Saturday the 19th day of September, 2026 at 12:30 P.M. through Video Conferencing/Other Audio-Visual Means. The following businesses were transacted in the meeting:

Ordinary Business:

1. To receive, consider and adopt the Audited Standalone Financial Statements of the company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and Auditors thereon.

2. To appoint a Director in place of Mr. Davender Singh (DIN: 09447213), who retires by rotation and being eligible, offers himself for re-appointment.

3. To re-appoint M/s. Garg Mendiratta and Associates, Chartered Accountants as the statutory auditors of the company and fix their remuneration.

Special Business:

4. To appoint M/s. SDK & Associates, Practicing Company Secretaries as the Secretarial Auditors of the Company for a period of five financial years from financial year 2026-2027 to financial year 2030-2031.

5. To approve variation in the objects of the Preferential Issue and in the utilization of the proceeds thereof, as approved by the members at the Extraordinary General Meeting held on March 20, 2026.

6. To approve the investment of funds in the securities of M/s. Infuze Well Private Limited under Section 186 of the Companies Act, 2013.

7. To approve material related party transaction — strategic investment by way of subscription to equity shares of M/s. Infuze Well Private Limited.

8. To approve the related party transactions.

The meeting concluded at 12:42 P.M.

You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,
FOR PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH
DIRECTOR
DIN: 09447213